Cerebrolysin

Cerebrolysin is the neurotrophic preparation that neuroregeneration researchers return to again and again. A standardised, brain-derived mixture of low-molecular-weight peptides and free amino acids, it's valued for a rare quality among research compounds: the proposed ability to mimic endogenous neurotrophic factors like BDNF, GDNF, NGF, and CNTF all at once. Preclinical models have explored its capacity to support neuronal survival, promote neuroplasticity and synaptogenesis, and modulate amyloid precursor protein processing across ischaemic injury, neurodegeneration, traumatic brain injury, and cognitive-performance paradigms. Every 60 mg vial is research-grade material, third-party verified to 98.6% purity, and prepared for clean, consistent handling. Supplied strictly for research purposes only.

• Mimics the action of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF) in preclinical models
• Supports neuronal survival and reduces apoptosis under ischaemic and hypoxic conditions
• Promotes synaptogenesis and neuroplasticity in cognitive-performance research
• Modulates amyloid precursor protein processing in neurodegeneration models
• Reduces neuroinflammation and oxidative stress in injured neural tissue
• Studied across stroke, traumatic brain injury, and dementia research paradigms
• Multi-target pleiotropic action distinct from single-receptor neuropeptides

Research Administration

Intramuscular or subcutaneous injection, 5–10 mg daily in research protocols; reconstitute prior to use

For research purposes only. Not for human consumption.

• Store at −20°C in a dry, sealed environment
• Reconstitute with bacteriostatic water; use within 30 days at 4°C
• Avoid repeated freeze-thaw cycles
• Supplied for research purposes only — not for human or veterinary use